Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
18F-FMISO PET/CT and MRI in Recurrent Glioblastoma
NCT03573986Phase 1Terminated
- Sponsor
- Abramson Cancer Center
- Start
- Apr 2018
- Primary completion
- Jan 2020
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial, sponsored by Abramson Cancer Center. Primary endpoint: Number of Adverse Events at 2 years. Started Apr 2018; status: terminated.
Beyond the preview
Go deeper on NCT03573986.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03573986.